Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06295809 2026-03-27

INTerpath-007

Phase 2/3 Completed

46 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT06788990 2026-03-23

FORTIFI-HN01

Phase 2/3 Recruiting

650 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT04613596 2026-03-18

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Phase 2/3 Recruiting

806 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04093167 2026-03-11

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Phase 2/3 Recruiting

230 enrolled

Thoracic

Lung Neoplasms

NCT06236438 2026-02-23

LIVIGNO-4

Phase 2/3 Recruiting

840 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3 Active not recruiting

420 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

542 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Phase 2/3 Active not recruiting

450 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

Phase 2/3 Not yet recruiting

750 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

AHEAD-MERIT

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

MountainTAP-29

HexAgon-HN

INTerpath-007

FORTIFI-HN01

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

LIVIGNO-4

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

SKYSCRAPER-06

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

TeLuRide-008